CD22 and acute lymphoblastic leukemia: Satake et al., used a DBCO-modified ASO against a critical transcription factor in precursor B-cell (preB) acute lymphoblastic leukaemia (ALL) to react with an azide modified anti-CD22 Ab, and showed preferential cytotoxicity in preB cells and doubling of the life expectancy in ALL model mice[116].